NASDAQ:ACIU

AC Immune Q3 2026 Earnings Results & Report

AC Immune logo
$2.13 +0.04 (+1.67%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$2.11 -0.02 (-1.12%)
As of 05:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AC Immune beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.16 versus the -$0.18 consensus estimate, while revenue of $3.88 million topped the $1.62 million estimate by $2.26 million.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

AC Immune EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

AC Immune Revenue Results

Actual Revenue
$3.88 million
Expected Revenue
$1.62 million
Beat/Miss
Beat by +$2.26 million
YoY Revenue Growth
N/A

Earnings Documents

AC Immune Q3 2026 Earnings FAQ

AC Immune (NASDAQ:ACIU) reported earnings of -$0.16 per share for Q3 2026, beating the consensus estimate of -$0.18. The report was announced on Wednesday, November 4, 2026.

AC Immune reported revenue of $3.88 million for Q3 2026, against a consensus estimate of $1.62 million.

AC Immune Earnings Headlines

HC Wainwright Comments on AC Immune FY2026 Earnings
“Madam President” [Pic inside]
Former CIA and Presidential advisor Jim Rickards says President Trump has a big surprise coming, despite the lame duck label. He calls it Trump's grand finale. Rickards says no president has made this move on the way out the door in more than 100 years, and the new Congress could be powerless to stop it. It centers on a fortune he estimates at $150 trillion.tc pixel
AC Immune Third Quarter 2026 Financial and Corporate Update
See More AC Immune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AC Immune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AC Immune and other key companies, straight to your email.

About AC Immune

AC Immune (NASDAQ:ACIU) SA is a Swiss biopharmaceutical company focused on developing precision medicines and diagnostic products for neurodegenerative diseases. Its research programs address conditions including Alzheimer’s and Parkinson’s diseases, as well as other neurological disorders.

The company’s pipeline includes immunotherapies and small-molecule drug candidates designed to target proteins associated with neurodegeneration. AC Immune also develops diagnostic approaches and uses proprietary technology platforms, including SupraAntigen and Morphomer, to identify and advance potential treatments.

Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune conducts research and clinical development through its own programs and collaborations with pharmaceutical and biotechnology partners. Co-founder Andrea Pfeifer serves as chief executive officer.

View AC Immune Profile